Investments
144Portfolio Exits
48Funds
11Partners & Customers
2Service Providers
1About Foresite Capital
Foresite Capital is a multi-stage healthcare and life sciences investment firm that applies rigorous scientific and data-driven approaches to investment analysis. The firm has $2.2 billion in assets under management. Foresite Capital takes a collaborative approach to investing with its portfolio companies by providing a multidisciplinary team of scientists, engineers, analysts, and clinicians who understand the unique business models in healthcare in addition to capital. The company aims to address areas of great unmet clinical need over the long term by funding promising healthcare and life sciences businesses at all stages of their life cycles. Its portfolio also emphasizes companies that are employing the tools of data science and machine intelligence in healthcare. Foresite Capital is based in San Francisco with an office in New York.
Want to inform investors similar to Foresite Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Foresite Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Foresite Capital in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Research containing Foresite Capital
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Foresite Capital in 3 CB Insights research briefs, most recently on Feb 16, 2021.
Latest Foresite Capital News
Apr 28, 2023
Foresight Diagnostics Aurora CO based developer of cancer detection tests raises USD 58.75M Series B funding The round led by Foresite Capital
Foresite Capital Investments
144 Investments
Foresite Capital has made 144 investments. Their latest investment was in Foresight Diagnostics as part of their Series B on April 4, 2023.
Foresite Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/27/2023 | Series B | Foresight Diagnostics | $58.75M | Yes | 1 | |
2/13/2023 | Series B - III | Cerevance | $51M | No | 8 | |
2/7/2023 | Series B - II | Evonetix | $24M | No | 17 | |
10/13/2022 | Series B | |||||
10/12/2022 | Series B |
Date | 4/27/2023 | 2/13/2023 | 2/7/2023 | 10/13/2022 | 10/12/2022 |
|---|---|---|---|---|---|
Round | Series B | Series B - III | Series B - II | Series B | Series B |
Company | Foresight Diagnostics | Cerevance | Evonetix | ||
Amount | $58.75M | $51M | $24M | ||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 1 | 8 | 17 |
Foresite Capital Portfolio Exits
48 Portfolio Exits
Foresite Capital has 48 portfolio exits. Their latest portfolio exit was XinThera on May 09, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
5/9/2023 | Acquired | 1 | |||
9/8/2022 | Asset Sale | 2 | |||
8/10/2022 | Acq - Pending | 2 | |||
Date | 5/9/2023 | 9/8/2022 | 8/10/2022 | ||
|---|---|---|---|---|---|
Exit | Acquired | Asset Sale | Acq - Pending | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 1 | 2 | 2 |
Foresite Capital Fund History
11 Fund Histories
Foresite Capital has 11 funds, including Foresite Capital Opportunity Fund V.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
3/3/2022 | Foresite Capital Opportunity Fund V | $173M | 3 | ||
2/25/2021 | Foresite Capital Fund V | $400M | 3 | ||
5/3/2018 | Foresite Capital Fund IV | Multi-Stage Venture Capital | Closed | $668M | 1 |
7/29/2015 | Foresite Capital Fund III | ||||
4/1/2014 | Foresite Capital Fund II |
Closing Date | 3/3/2022 | 2/25/2021 | 5/3/2018 | 7/29/2015 | 4/1/2014 |
|---|---|---|---|---|---|
Fund | Foresite Capital Opportunity Fund V | Foresite Capital Fund V | Foresite Capital Fund IV | Foresite Capital Fund III | Foresite Capital Fund II |
Fund Type | Multi-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | $173M | $400M | $668M | ||
Sources | 3 | 3 | 1 |
Foresite Capital Partners & Customers
2 Partners and customers
Foresite Capital has 2 strategic partners and customers. Foresite Capital recently partnered with Lilt on July 7, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
7/25/2022 | Licensor | United States | The partnership will integrate Lilt 's translation capabilities into Foresite 's offering . | 1 | |
Partner |
Date | 7/25/2022 | |
|---|---|---|
Type | Licensor | Partner |
Business Partner | ||
Country | United States | |
News Snippet | The partnership will integrate Lilt 's translation capabilities into Foresite 's offering . | |
Sources | 1 |
Foresite Capital Service Providers
1 Service Provider
Foresite Capital has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel | General Counsel |
Service Provider | |
|---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
Foresite Capital Team
7 Team Members
Foresite Capital has 7 team members, including current Founder, Chief Executive Officer, Jim Tananbaum.
Name | Work History | Title | Status |
|---|---|---|---|
Jim Tananbaum | Prospect Venture Partners, Theravance Biopharma, Sierra Ventures, and Merck & Co. | Founder, Chief Executive Officer | Current |
Name | Jim Tananbaum | ||||
|---|---|---|---|---|---|
Work History | Prospect Venture Partners, Theravance Biopharma, Sierra Ventures, and Merck & Co. | ||||
Title | Founder, Chief Executive Officer | ||||
Status | Current |
Compare Foresite Capital to Competitors
Thompson Street Capital Partners is a private equity firm that focuses on investing in life sciences and healthcare, software and technology, and business and consumer services and products sectors. Thompson Street Capital Partners was founded in 2000 and is based in Saint Louis, Missouri.
DBL Partners is a venture capital firm that invests in the cleantech, information technology, sustainable products and services, and healthcare sectors to deliver venture capital returns and enable social, environmental, and economic benefits. It was founded in 2002 and is based in San Francisco, California.
Discovery Ventures is a healthcare venture capital fund. The firm seeks to invest in the health tech, gene therapy, bionics, stem cells, nanotechnology, and biotechnology sectors. It was founded in 1998 and is based in Wilmington, Delaware.
Slow Ventures is an early-stage focused venture capital firm. The firm invests in companies operating in commercial products, commercial services, consumer services, financial services, pharmaceuticals, and other sectors. It was founded in 2011 and is based in San Francisco, California.
Sequoia is a venture capital firm. It seeks to invest in companies operating in the information technology, healthcare, manufacturing, mobile, nanotechnology, financial service, internet, energy, media, and retail sectors. The company was founded in 1972 and is based in Menlo Park, California.
Johnson & Johnson Innovation is the venture capital subsidiary of Johnson & Johnson. JJI is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, Johnson & Johnson Innovation determines the success of an investment's performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.